Irinotecan (CPT-11): A brief overview

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 10-11, 1996, Pages 1000-1004

  Rivory, Laurent P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Camptothecin; CPT 11; Irinotecan; Metabolism; Pharmacokinetics; Topoisomerase I inhibitors

Indexed keywords

CAMPTOTHECIN; DRUG METABOLITE; IRINOTECAN;

BONE MARROW SUPPRESSION; CONFERENCE PAPER; DIARRHEA; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHARMACOGENETICS; PHARMACOKINETICS; STRUCTURE ACTIVITY RELATION;

EID: 0029844394     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb01158.x     Document Type: Conference Paper

References (29)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966; 88: 3888-90.
2. Sawada S, Okajima S, Aiyama R et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull. 1991; 39: 1446-54.
3. Potmesil M. Camptothecins: From bench research to hospital wards. Cancer Res. 1994; 54: 1431-9.
4. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 1989; 49: 5016-22.
5. Hsiang Y-H, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985; 260: 14873-8.
6. Hsiang Y-H, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988; 48: 1722-6.
7. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem. 1991; 266: 20418-23.
8. Hertzberg RP, Caranfa MJ, Hecht S. On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 1989; 28: 4629-38.
9. Hsiang Y-H, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989; 49: 5077-82.
10. Christiansen K, Dirac Svejstrup AB, Andersen AH, Westergaard O. Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination. J. Biol. Chem. 1993; 268: 9690-701.
11. Wall ME, Wani MC. Antineoplastic agents from plants. Annu. Rev. Pharmacol. Toxicol. 1977; 17: 117-32.
12. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 1992; 81: 676-84.
13. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J. Med. Chem. 1994; 37: 40-6.
14. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure - activity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence for a specific receptor site and relation to antitumor activity. Cancer Res. 1989; 49: 1465-9.
15. Scott DO, Bindra DS, Sutton SC, Stella VJ. Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab. Dispos. 1994; 22: 438-42.
16. Rivory LP, Robert J. Reverse-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite in plasma. J. Chromatogr. 1994; 661: 133-41.
17. Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 1994; 54: 6330-3.
18. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl oxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res. 1994; 54: 427-36.
19. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51: 4187-91.
20. Satoh T, Hosokawa M, Atsumi R, Susuki W, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl oxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 1994; 17: 662-4.
21. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol. 1995; 6: 141-51.
22. Rivory LP, Bowles MR, Robert J, Pond SM. The conversion of CPT-11 (irinotecan) to its active metabolite, SN-38, by human liver carboxylesterase Biochem. Pharmacol. 1996 (in press).
23. Rivory LP, Riou J-F, Haaz M-C et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 1996; 56: 3689-94.
24. Rivory LP, Robert J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan (CPT-11). Cancer Chemother. Pharmacol. 1995; 36: 176-9.
25. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res. 1994; 54: 3723-5.
26. Gandia D, Abigerges D, Armand J-P et al. CPT-11-Induced cholinergic effects in cancer patients. J. Clin. Oncol. 1993; 11: 196-7.
27. Kawato Y, Seiguchi M, Akahane K et al. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J. Pharm. Pharmacol. 1993; 45: 444-8.
28. Araki E, Ishikawa M, Iigo M, Koide M, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 1993; 84: 697-702.
29. Abigerges D, Armand J-P, Chabot GG et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl Cancer Inst. 1994; 86: 446-9.